Objectives: Extracellular adenosine has tissue-protective potential in several conditions. Adenosine levels are regulated by a close interplay between nucleoside transporters and adenosine kinase. On the basis of the evidence of the role of adenosine kinase in regulating adenosine levels during hypoxia, we evaluated the effect of adenosine kinase on lung injury. Furthermore, we tested the influence of a pharmacologic approach to blocking adenosine kinase on the extent of lung injury. Design: Prospective experimental animal study. Setting: University-based research laboratory. Subjects: In vitro cell lines, wild-type and adenosine kinase +/mice. Interventions: We tested the expression of adenosine kinase during inflammatory stimulation in vitro and in a model of lipopolysaccharide inhalation in vivo. Studies using the adenosine kinase promoter were performed in vitro. Wild-type and adenosine kinase +/mice were subjected to lipopolysaccharide inhalation. Pharmacologic inhibition of adenosine kinase was performed in vitro, and its effect on adenosine uptake was evaluated. The pharmacologic inhibition was also performed in vivo, and the effect on lung injury was assessed.
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For information regarding this article, E-mail: peter.rosenberger@medizin. uni-tuebingen.de diseases (7, 8) . Extracellular adenosine is generated by the conversion of extracellular adenosine triphosphate (ATP) to adenosine diphosphate (ADP) and adenosine monophosphate (AMP) as a result of dephosphorylation by the enzymes ectonucleotidase triphosphate diphosphohydrolase (CD39) and ecto-5′-nucleotidase (CD73), which are primarily located on the vascular endothelium (9) . Signal transduction by extracellular adenosine then functions through the four purinergic G-protein-coupled adenosine receptors. These adenosine receptors are widely distributed throughout the organism, and all of these receptors are proposed to mediate tissue protection (10, 11) . Following its generation, adenosine is mainly cleared from the extracellular space by the equilibrative nucleoside transporters (ENTs) and concentrative nucleoside transporters, resulting in the movement of adenosine into cells. In the intracellular space, adenosine is then either degraded to inosine via adenosine deaminase (12) or converted to AMP and ADP by adenosine kinase (ADK) (13) . Therefore, the intracellular enzyme ADK also regulates the extracellular adenosine levels. The inhibition of ADK results in elevated extracellular adenosine levels; therefore, this inhibition has a high therapeutic potential for protecting tissue in several pathologic conditions (13, 14) .
Because changes in the vascular barrier function and infiltration of leukocytes into the alveolar space are key processes during the initial stages of lung injury, we sought to describe the role of ADK in the development of this condition. In addition, we evaluated whether 5-iodotubercidin (ITU) can inhibit ADK, as a possible pharmacologic intervention that acts on ADK to ameliorate the changes in lung injury.
MATERIALS AND METHODS

Ethic Statement
All animal protocols were in accordance with the German guidelines for the use of living animals and were approved by the Institutional Animal Care and Use Committee of the Tübingen University Hospital and the Regierungspräsidium, Tübingen. For experiments using materials from human blood samples, ethics committee approval was obtained, and each participant provided written informed consent.
Mice ADK +/mice (Adk tm1Bois ) were generated, validated, and characterized as described previously (15) . For further details, please see the supplement material (Supplemental Digital Content 1, http://links.lww. com/CCM/B482).
Transcriptional Analysis
To assess the relative expression levels of ADK, we tested various tissues from wild-type (WT) and ADK +/mice. For details, please see the online supplement (Supplemental Digital Content 1, http://links. lww.com/CCM/B482).
In a separate experiment, human lung epithelial A549 cells were grown to confluence and stimulated with tumor necrosis factor (TNF)-α (100 ng/mL), interleukin (IL)-6 (20 ng/mL), or IL-1β (20 ng/ mL) for 2, 4, 8, and 24 hours. For further details, please see A, ADK messenger RNA concentrations in the lung tissue from mice 4 hr after sodium chloride (NaCl) or LPS inhalation (mean ± sem, n = 4 per group; *p < 0.05 as indicated). B, Analysis of murine pulmonary ADK protein concentration 4 hr after NaCl or LPS inhalation. Protein samples were pooled from n = 7 per group; β-actin levels were used to control the protein-loading conditions. C, Immunohistochemistry of ADK in murine lungs using cytokeratin as a structural epithelial marker. Tissue sections were stained with antibodies specific for ADK (green) and epithelial cytokeratin (red). The colocalization of ADK with cytokeratin is shown in yellow in the overlaid image. 4′,6-diamidin-2-phenylindol (DAPI) (blue) served as a nuclear identifier (magnification ×400, n = 3 per group). Isotype immunglobulin (IgG) and negative control staining are shown in Supplemental Figure E1B 
Protein Analysis
Cell culture and mouse tissue samples were normalized for the protein levels before being applied to sodium dodecyl sulfate containing polyacrylamide gels and were processed according to the standard protocols.
Immunofluorescence Staining
Lung epithelial A549 cells and murine tissues for immunofluorescence staining of the lungs were harvested and processed according to the standard protocols. For further details, please see the supplement material (Supplemental Digital Content 1, http://links.lww.com/CCM/B482).
Immunohistochemistry
Immunohistochemistry was performed as previously described (7, 16) .
Isolation of Human Neutrophils and the Transepithelial Migration Assay
Peripheral blood was taken from healthy donors into Sarstedt Monovettes containing sodium citrate (Sarstedt, Nümbrecht, Germany), and neutrophils were isolated as previously described (17) . For transendothelial migration studies, A549 cells were grown on the basolateral aspect of permeable transwell inserts (0.4-μm pore size and 6.5-mm diameter) until they were confluent. Migration assays were performed as described elsewhere (17) . In a subset of experiments, ADK A549 cells were inhibited by ITU for 30 minutes before the transepithelial migration assay was started.
Macromolecule Paracellular Permeability Assay (Flux)
Human A549 cells were seeded and grown to a monolayer on the permeable membrane as described above. Flux assays were performed as previously described (18) .
Measurement of the Intracellular Adenosine and Adenosine Uptake
Human lung epithelial A549 cells were cultured for 2 days in six-well plates to confluence. At the start of the experiment, the cell media were replaced with Hank's Balanced Salt Solution+ containing 10 or 25 μm/mL ITU. As a control, we used cells without ITU treatment, and to control adenosine reuptake, we administered 25 μm/mL ITU plus 10 μm/mL dipyridamole, which is a cellular adenosine uptake inhibitor. For details, please see the online supplement (Supplemental Digital Content 1, http://links.lww.com/CCM/B482).
ADK Reporter Assays
Promoter analysis and identification of both the transcription start site and the potential nuclear factor κ-light-chainenhancer of activated B-cells (NF-κB)-binding sites were A, Confluent pulmonary A549 epithelial cells were exposed to tumor necrosis factor (TNF)-α (100 ng/mL) or interleukin (IL)-6 (20 ng/mL) for 2, 4, 8, and 24 hr or (B) A549 cells were stimulated for 24 hr with increasing concentrations of TNF-α (0, 1, 10, and 100 ng/mL) or IL-6 (0, 0.2, 2, and 20 ng/mL). Data are analyzed and displayed as the fold change in transcripts relative to the baseline of nonstimulated control samples (mean ± sem, n ≥ 4 per group; *p < 0.05, **p < 0.01, and ***p < 0.001 as indicated using Dunnett multiple comparison). C, Expression of ADK protein in A549 epithelial cells exposed to increasing concentrations of TNF-α (0, 1, 10, and 100 ng/mL) or IL-6 (0, 0.2, 2, and 20 ng/mL). D, Immunofluorescence staining for human ADK in nonstimulated confluent pulmonary A549 cells compared with cells exposed to TNF-α (100 ng/mL) for 24 hr. Sections were stained using an antibody specific for human actin (Alexa 594; red) for structural depiction and 4′,6-diamidin-2-phenylindol (DAPI) (blue) as a nuclear marker. To specify the repression of ADK protein after inflammatory stimulation of these A549 cells, we used Alexa 488 (green). Isotype immunglobulin (IgG) and negative control staining are shown in Supplemental Figure E1A 
NF-κB Chromatin Immunoprecipitation
The chromatin immunoprecipitation (ChIP) assay (CHP1; Sigma-Aldrich, Munich, Germany) was performed according to the manufacturer's instructions. As the ChIP-qualified antibody of interest, we used the NF-κB antibody anti-NF-κB p105/p50-ChIP Grade Abcam (ab7971; Cambridge, MA). For the polymerase chain reaction detection of ADK, we used the following primers: ttt cct agg ctg agg ctt ccc (forward) and tca gct ccc tgt aac agc act (reverse).
Bronchoalveolar Lavage
After animals were killed, bronchoalveolar lavage fluid (BALF) was collected by performing a tracheotomy and flushing the lungs three times with 0.6 mL of phosphate-buffered saline.
For further details, please see the supplement material (Supplemental Digital Content 1, http://links.lww.com/CCM/B482).
Data Analysis
We performed statistical analysis by using one-way analysis of variance to determine the differences between the groups by using Dunnett post hoc analysis. Unpaired Student t test was used where appropriate. A value of p less than 0.05 was considered to be statistically significant.
RESULTS
ADK Is Repressed During Pulmonary Inflammation in Mice
In an initial experiment, we sought to evaluate whether the ADK levels change during lung injury in mice. For this, we The IgG control and positive control are shown. C, A549 cells were transfected with the full-length (FL) promoter or the indicated constructs containing mutations in the potential NF-κB-binding site and then a reporter assay for luciferase activity was conducted after exposure to 100 ng/mL tumor necrosis factor (TNF)-α for 24 hr. The results reflect the fold change in luminescence relative to nonstimulated control samples. To control for the transcriptional activity of NF-κB, cells were transfected with pNF-κB-Luc. Data are normalized to the background vector (pGL4.17) and total protein (mean ± sem, n = 4 per group, ***p < 0.001 as indicated). GAPDH = glycerinaldehyd-3-phosphat-dehydrogenase. To detect the intracellular adenosine production, we used the adenosine uptake inhibitor dipyridamole. The intracellular adenosine levels were determined by high performance liquid chromatography. Both of the ITU concentrations led to a continuous increase in the intracellular adenosine levels over time (n = 5-6). B, A549 cells were treated with the indicated concentrations of ITU, and adenosine transport/uptake was quantified. Control experiments were performed in the presence of dipyridamole (20 μM) (mean ± sem, n = 4-6).
Critical Care Medicine www.ccmjournal.org e185 exposed mice to a lung injury model involving lipopolysaccharide (LPS) inhalation. Following this, we found a significant repression of ADK at the transcriptional level in pulmonary tissue (Fig. 1A) . The protein levels of ADK also reflected this finding ( Fig. 1B) . To illustrate the repression of ADK, we performed immunofluorescence staining of the pulmonary tissue. The ADK staining in pulmonary tissue sections showed reduced ADK-specific immunofluorescence following LPS exposure. An epithelial marker, cytokeratin, was used for coimmunostaining ( Fig. 1C; and Supplemental Fig. E1 , Supplemental Digital Content 2, http://links.lww.com/CCM/B483).
Expression of Epithelial ADK Is Diminished by Inflammatory Cytokines In Vitro via NF-κB
To determine whether ADK expression is regulated at the transcriptional level in response to proinflammatory stimuli, we exposed confluent pulmonary epithelial cell monolayers (A549) to TNF-α (100 ng/mL), IL-6 (20 ng/mL), or IL-1β (20 ng/mL) for 0, 2, 4, 8, and 24 hours. In addition, we measured ADK transcriptional expression following exposure to different concentrations of these cytokines. We found significant repression of ADK at the transcriptional level, and we detected an early onset of repression, within 2 hours of the start of exposure (Fig. 2, A and B; and Supplemental Figure E2A and E2B, Supplemental Digital Content 3, http://links.lww.com/CCM/B484). To verify our results, we examined ADK expression at the protein level in A549 cells by using different cytokine concentrations. The protein analysis confirmed the results that were observed at the transcriptional level, showing repression of ADK protein expression after proinflammatory stimulation with TNF-α, IL-6, or IL-1β ( Fig. 2C; and Supplemental Figure E2C , Supplemental Digital Content 3, http://links.lww.com/CCM/B484). To visualize the repression of ADK, we used immunofluorescence staining of alveolar A549 cells. Following 24 hours of stimulation with TNF-α, there was reduced ADK immunofluorescence ( Fig. 2D; and Supplemental To gain further insight into the regulatory mechanisms controlling ADK at the transcriptional level, we performed a transcription factor-binding site analysis of the ADK promoter region by using the available public databases. We identified one NF-κB-binding site at -309 bp (Fig. 3A) . To identify the functional role of this NF-κB-responsive element, we first tested the binding activity of NF-κB to the ADK promoter in A549 cells by using ChIP assay. There was a strong binding response of NF-κB after stimulation with TNF-α, which indicated an NF-κB-driven mechanism that regulated ADK production at the transcriptional level ( Fig. 3B) . To assess the functional role of the NF-κB-binding site, we designed luciferase reporter constructs that expressed the putative ADK-FL promoter (Fig. 3C) . In addition, we manufactured site-directed mutations in the NF-κB response element regions to prevent NF-κB binding. We transfected A549 cells with the promoter constructs and stimulated the cells with 100 ng/mL TNF-α for 24 hours. The luciferase activity of the unmodified ADK-FL promoter was strongly reduced in response to the inflammatory stimulus. Following mutation of the binding site for NF-κB (∆309), this repression of luciferase activity was reversed.
Extracellular Adenosine Levels Are Influenced by ADK, Reducing Transepithelial Migration and Flux
Because high extracellular adenosine levels are known to be involved in tissue protection during ischemic or inflammatory events, we first tested a potential increase in intracellular adenosine by blocking ADK through the addition of ITU to pulmonary epithelial (A549) cells. Eight hours after incubation with either 25 or 10 μM ITU, the intracellular adenosine levels increased approximately three-fold compared with the starting adenosine level (Fig. 4A) . Compared with the controls, the intracellular adenosine concentration was approximately two-fold higher 8 hours after blocking ADK with ITU.
To determine the impact of adenosine uptake after adenosine enhancement as a result of the ITU-mediated inhibition of intracellular conversion of adenosine, we added adenosine to the extracellular space and detected the changes in extracellular adenosine concentration over time. We used untreated cells as a negative control and treatment with the adenosine uptake inhibitor dipyridamole as a positive control. We found that the loss of extracellular adenosine from the supernatant was significantly attenuated after ADK inhibition by ITU. The extracellular adenosine levels in all ITU-treated samples were elevated in a concentration-dependent manner, but these levels were influenced by ENT-dependent adenosine uptake inhibition with dipyridamole ( Fig. 4B) .
A hallmark of inflammation is the recruitment of PMNs to injured tissue, where they cross the endothelial and epithelial barrier in a transmigration process (19) . Therefore, we sought to evaluate the influence of ADK inhibition on this process. For this, we used a transepithelial migration assay that was previously described (18) . We found a significant reduction in the transepithelial migration of PMNs when they were treated with 25 μM ITU (Fig. 5A) . We were also able to detect a reduction in paracellular permeability when testing fluorescein isothiocyanate-dextran flux following preincubation of the epithelium with ITU (Fig. 5B) .
Reduced Pulmonary Inflammation in ADK +/-Mice Following LPS Inhalation
As homozygous ADK-deficient mice are not viable, we exposed heterozygous ADK +/mice to a model of lung injury induced through LPS inhalation. Before the start of the experiment, we validated the diminished ADK expression in several organs of these mice (Supplemental Fig.  E4A and E4B, Supplemental Digital Content 5, http://links. lww.com/CCM/B486) (15) . Following exposure to LPS, ADK +/mice had significantly reduced cell infiltration, total protein content, and myeloperoxidase amount in BALF compared with WT controls (Fig. 6 A-C) . Diminished TNF-α, IL-1β, and IL-6 cytokine levels corroborated our findings of an attenuated inflammatory response in ADK +/mice ( Fig. 6 D-F) . The decreased inflammation in ADK +/mice was also associated with the decreased infiltration of PMNs into pulmonary tissue compared with WT controls (Fig. 6G; and Supplemental Fig.  E5 , Supplemental Digital Content 6, http://links.lww.com/CCM/ B487). We found an increased expression of the adenosine receptor 2B in these animals (Supplemental Fig. E6 , Supplemental Digital Content 7, http://links.lww.com/CCM/B488).
Pharmacologic Inhibition of ADK Attenuates ALI
Encouraged by the detected lung tissue protection in ADK +/mice, we evaluated the pharmacologic inhibition of ADK in WT animals as a potential therapeutic approach to ALI. For this, we administered the specific ADK inhibitor ITU via inhalation over a period of 30 minutes at concentrations of 0.1 mg/kg Figure 6 . Inflammatory changes are attenuated in ADK +/mice during lung injury. Mice were exposed to lipopolysaccharide (LPS) through inhalation, and the (A) cell count, (B) protein, (C) myeloperoxidase (MPO) content, (D) tumor necrosis factor (TNF)-α, (E) interleukin (IL)-1β, and (F) IL-6 levels were measured in the bronchoalveolar lavage fluid (BALF) of adenosine kinase (ADK) heterozygous (ADK +/-) and wild-type (WT) mice 4 hr after sodium choloride (NaCl) or LPS inhalation (mean ± sem; n ≥ 5 per group, **p < 0.01 and ***p < 0.001 according to one-way analysis of variance testing). G, Staining of infiltrating polymorphonuclear neutrophil cells in pulmonary histologic tissue sections of ADK +/and WT mice 4 hr after exposure to LPS or NaCl through inhalation (magnification ×400). Representative images of histologic lung sections, which were selected from three examined mice per group, are shown.
Critical Care Medicine www.ccmjournal.org e187 (≙ 3.33 μg/kg min) and 0.01 mg/kg (≙ 0.33 μg/kg min) immediately after sodium chloride or LPS inhalation. As shown in the in vitro experiments using lung epithelial cells, ITU blocks ADK; as a result, the extracellular adenosine levels increase. Following the inhalation of ITU, we found significantly attenuated pulmonary inflammatory changes ( Fig. 7 A-C) . Low cytokine levels of TNF-α, IL-1β, and IL-6 in the BALF confirmed that ITU was protective during pulmonary inflammation (Fig. 7 D-F) .
Reduced numbers of neutrophils infiltrating into the lung tissue were confirmed by immunohistochemistry ( Fig. 7G) . Taken together, our findings provide evidence that the pharmacologic inhibition of ADK decreases the pulmonary damage in ALI.
DISCUSSION
To date, lung injury significantly contributes to in-hospital mortality (20) . A crucial component of lung injury is the loss of alveolar-capillary function, which results in the trafficking of neutrophils from the vascular space into the alveolar space and in the development of tissue edema (1) . Based on previous observations that ADK has the potential to protect barrier function during hypoxia, we evaluated the role of ADK during ALI (21) . We report here that ADK is repressed during inflammation both in vitro and in vivo. This repression translates into a protective response during pulmonary inflammation as observed in animal experiments involving genetic repression of ADK. Furthermore, pharmacologic studies using ITU have demonstrated that the in vivo inhibition of ADK attenuates tissue injury during pulmonary inflammation (for mechanistic insight, see Fig. 8 ).
In the initial experiments, we observed both the transcriptional and translational repression of ADK during an acute inflammatory process in vitro. This observation is in line with our previous finding that ADK repression was induced in endothelial cells and intestinal epithelial cells during tissue hypoxia (21) . To gain more insight into the regulation of ADK, we focused on NF-κB because it is one of the transcription factors that initiate inflammation (22) . For this approach, we first analyzed the promoter region of ADK and found one putative response element region for NF-κB binding in the promoter region. As a proof of concept, we first checked for NF-κB binding during in vitro inflammatory conditions in lung epithelial cells by using ChIP assay. . Pharmacologic inhibition of adenosine kinase (ADK) decreases pulmonary inflammation. Mice were exposed to lipopolysaccharide (LPS) through inhalation, and the (A) cell count, (B) protein (C) myeloperoxidase (MPO) content, (D) tumor necrosis factor (TNF)-α, (E) interleukin (IL)-1β, and (F) IL-6 levels were measured in the bronchoalveolar lavage fluid (BALF) with and without pharmacologic inhibition of ADK by 5-iodotubercidin (ITU) in wild-type (WT) animals 4 hr after sodium choloride (NaCl) or LPS inhalation (mean ± sem; n ≥ 5 per group, *p < 0.05, **p < 0.01, and ***p < 0.001 according to one-way analysis of variance testing). G, Staining of infiltrating polymorphonuclear neutrophil cells in pulmonary histologic tissue sections of WT mice at 4 hr after LPS or NaCl inhalation, mice were also treated with or without ITU in different concentrations for 30 min following LPS inhalation (magnification ×400). Representative images of histologic lung sections selected from three mice per group are shown. OD = optical density.
Our results indicated strong binding of NF-κB to the putative ADK promoter. Following this, we measured the expression level of ADK in vivo. After exposure to LPS, we also observed the repression of ADK in vivo. To further investigate the functional effects of the ADK repression, we evaluated ADK +/mice, which had significant repression of ADK within the pulmonary tissue. We exposed these animals to LPS inhalation and observed significantly reduced numbers of infiltrating cells and levels of cytokines and other inflammatory markers in BALF from these animals. This observation is in line with the rapid increase in extracellular adenosine and the transcriptional repression of ADK during hypoxia (21, 23) , and it might be a protective adaptation to the detrimental effects of pulmonary inflammation. The ADK repression increases the extracellular adenosine concentration, which has been reported to protect tissue in several conditions (24) . Extracellular adenosine signals through its known adenosine receptors (A1, A2A, A2B, and A3) to ameliorate inflammation (25) . We have demonstrated here that especially the adenosine 2B receptor is induced in our model of lung injury. This is in line with previous work showing the protective potential of the adenosine 2B receptor (26) . The protective roles of high extracellular adenosine levels and adenosine receptor signaling were also described during myocardial reperfusion injury, several neurologic conditions, arthritis, and colitis (25, (27) (28) (29) (30) (31) . To the best of our knowledge, repression of ADK during inflammatory tissue conditions, as present during lung injury, has not been shown before. This observation is novel and describes the endogenous anti-inflammatory adaptation to an acute inflammatory process.
To test the therapeutic potential of ADK inhibition for treating lung injury, we evaluated the pharmacologic inhibition of this enzyme. The intracellular enzyme ADK catalyzes the conversion of adenosine and ATP to AMP and ADP; as such, it plays a key role in controlling the cellular concentration of adenosine (32) . Consequently, an increase in the intracellular adenosine levels as a result of ADK inhibition enhances the extracellular adenosine levels (7) . To test this, we first evaluated the inhibition of ADK in vitro in epithelial cells by using ITU. In this experiment, we found a significant increase in the extracellular adenosine levels by inhibiting intracellular ADK. To evaluate the potential functional consequences, we next investigated whether the increased extracellular adenosine levels, which are mediated through ADK inhibition by ITU, interfere with the migration of neutrophils across the epithelial barrier. We observed improved epithelial barrier function, as well as diminished neutrophil migration, in response to ADK inhibition. To test whether ADK inhibition has a therapeutic effect in LPS-induced ALI, and whether it dampens the inflammatory response to LPS inhalation, we performed in vivo experiments using ITU administered at two concentrations after the onset of inflammation. We identified a strong inhibition of inflammation at the low concentration of ITU (0.01 mg/kg), as well as the diminished infiltration of cells, and lower protein and MPO content, and lower proinflammatory cytokine levels in the BALF. Other groups found similar tissue protection and decreased inflammation after the administration of ADK inhibitors. During experimental sepsis, the ADK inhibitor GP-1-515 showed to reduce the infiltration of neutrophils and the cytokine production, and this was associated with improved outcome of experimental animals (33) . These results were confirmed in another study using a model of paw inflammation, where again GP-1-515 demonstrated antiinflammatory potential through ADK inhibition (34) . We used the pharmacologic agent ITU here in this study through inhalation to test a lung-targeted intervention with ITU, which also has a low half maximal inhibitory concentration (IC50), that is comparable to the IC50 of GP-1-515. As such our results are in parts comparable to these previous studies although genetic deletion of ADK and in vitro models for the role of ADK were not included in this work done previously. Further studies have also confirmed our findings and have shown that the tissue-protective potential of ADK inhibition is also present during cerebral stroke (35, 36) and myocardial ischemia-reperfusion injury (37) . As such, our findings extend the previously known protective role of ADK inhibition to the field of pulmonary inflammation.
In summary, the results of our study are in line with previous investigations that demonstrated the tissue-protective properties of extracellular adenosine. In this study, inflammation promoted the transcriptional and translational repression of ADK both in vitro and in vivo. The active inhibition of ADK by ITU increased adenosine levels. The naturally initiated process of ADK repression seems to be a protective tissue adaptation to an inflammatory insult. Therefore, this study improves our understanding of the mechanisms underlying the regulation of extracellular adenosine by ADK and extends our understanding of the role of ADK during lung injury.
